U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H39O4.Na
Molecular Weight 414.5538
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM CHENODEOXYCHOLATE

SMILES

[Na+].[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC([O-])=O

InChI

InChIKey=WDFRNBJHDMUMBL-OICFXQLMSA-M
InChI=1S/C24H40O4.Na/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26;/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C24H39O4
Molecular Weight 391.5641
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chenodiol is the non-proprietary name for chenodeoxycholic acid, a naturally occurring human bile acid. It is a bitter-tasting white powder consisting of crystalline and amorphous particles freely soluble in methanol, acetone and acetic acid and practically insoluble in water. Chenodiol suppresses hepatic synthesis of both cholesterol and cholic acid, gradually replacing the latter and its metabolite, deoxycholic acid in an expanded bile acid pool. These actions contribute to biliary cholesterol desaturation and gradual dissolution of radiolucent cholesterol gallstones in the presence of a gall-bladder visualized by oral cholecystography. Bile acids may also bind the the bile acid receptor (FXR) which regulates the synthesis and transport of bile acids. Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Chenodiol

Approved Use

Chenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment.

Launch Date

1983
PubMed

PubMed

TitleDatePubMed
Toxicity of chenodeoxycholic acid in the rhesus monkey.
1975 Aug
Toxicity of chenodeoxycholic acid in the nonhuman primate.
1975 Jun
Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones.
1975 Oct
Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors.
2000 Dec
Differential modulation of cellular death and survival pathways by conjugated bile acids.
2001
Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
2001
[Advances in the diagnosis and treatment of cholelithiasis].
2001
LUV's lipid composition modulates diffusion of bile acids.
2001 Apr
Successful combination therapy--flunarizine, pentoxifylline, and cholestyramine--for spur cell anemia.
2001 Apr
Effects of bile salts and aliphatic ionic surfactants on human lymphocyte proliferation.
2001 Apr
Effect of bile acids on formation of azoxymethane-induced aberrant crypt foci in colostomized F344 rat colon.
2001 Aug 28
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
2001 Dec
Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids.
2001 Dec
Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A transcriptional control of a plausible bile acid transporter.
2001 Dec 14
Chenodeoxycholate is a potent inducer of the permeability transition pore in rat liver mitochondria.
2001 Feb
Differences in hepatic levels of intermediates in bile acid biosynthesis between Cyp27(-/-) mice and CTX.
2001 Feb
Cerebrotendinous xanthomatosis in three siblings from a Chinese family.
2001 Jan
Cerebrotendinous xanthomatosis presenting as "chologenic diarrhoea".
2001 Jul
Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells.
2001 Jun 1
Protective effect of carvedilol on chenodeoxycholate induction of the permeability transition pore.
2001 Jun 1
[Other antihyperlipidemic drugs with novel mechanism].
2001 Mar
[Cerebrotendinous xanthomatosis].
2001 Mar
[3-oxo-delta 4-steroid 5 beta-reductase deficiency].
2001 Mar
[3 beta-Hydroxysteroid-delta 5-oxidoreductase/isomerase deficiency].
2001 Mar
Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic acid but prevented by ursodeoxycholic acid.
2001 Mar
Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters.
2001 Mar
The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases.
2001 Mar
High-performance liquid chromatographic determination of ursodeoxycholic acid after solid phase extraction of blood serum and detection-oriented derivatization.
2001 Mar
Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
2001 Mar
Chenodeoxycholic treatment of cerebrotendinous xanthomatosis.
2001 Mar 13
Enhancement of endothelial nitric oxide production by chenodeoxycholic acids in patients with hepatobiliary diseases.
2001 May
Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects.
2001 May
Apoptotic activity of novel bile acid derivatives in human leukemic T cells through the activation of caspases.
2001 May
Green tea upregulates the low-density lipoprotein receptor through the sterol-regulated element binding Protein in HepG2 liver cells.
2001 Nov
Cerebrotendinous xanthomatosis.
2001 Nov 13
Bile acids regulate RANTES gene expression through its cognate NF-kappaB binding sites.
2001 Nov 16
Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression.
2001 Nov 9
Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids.
2001 Oct
Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids.
2001 Sep
Guest-responsive fluorescence variations of gamma-cyclodextrins labeled with hetero-functionalized pyrene and tosyl moieties.
2002 Feb
Use of ursodeoxycholic acid in patients with liver disease.
2002 Feb
Induction of cyclooxygenase-2 by tumor promoters in transformed and cytochrome P450 2E1-expressing hepatocytes.
2002 Jan
Bile salts modulate chronic ethanol-induced hepatotoxicity.
2002 Jan-Feb
Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor.
2002 Jul 19
Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1.
2002 Jul 26
Participation of two members of the very long-chain acyl-CoA synthetase family in bile acid synthesis and recycling.
2002 Jul 5
Characterization of rat liver bile acid acyl glucuronosyltransferase.
2002 Mar
[Treatment of cholestatic liver diseases].
2002 Mar 15
Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism.
2002 May
A natural product that lowers cholesterol as an antagonist ligand for FXR.
2002 May 31
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dose range for Chenodiol is 13 to 16 mg/kg/day in two divided doses, morning and night, starting with 250 mg b.i.d. the first two weeks and increasing by 250 mg/day each week thereafter until the recommended or maximum tolerated dose is reached. If diarrhea occurs during dosage buildup or later in treatment, it usually can be controlled by temporary dosage adjustment until symptoms abate, after which the previous dosage usually is tolerated. Dosage less than 10 mg/kg usually is ineffective and may be associated with increased risk of cholecystectomy, so is not recommended.
Route of Administration: Oral
Hepatocytes were treated with Chenodiol at 10, 30, and 100 uM for 48 h, and RNA was extracted for real-time PCR analysis. Chenodiol markedly suppressed CYP7A1, the rate-limiting enzyme of bile acid synthesis, but only moderately (35%) down-regulated CYP8B1 at a high concentration of 100uM. Chenodiol increased the two major target genes of the farnesoid X receptor (FXR), namely the small heterodimer partner (SHP) by fourfold, and markedly induced fibroblast growth factor 19 (FGF19) over 100-fold.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:14:07 GMT 2023
Edited
by admin
on Fri Dec 15 15:14:07 GMT 2023
Record UNII
6V4571KSKE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SODIUM CHENODEOXYCHOLATE
INCI  
Official Name English
CHENODEOXYCHOLIC ACID, SODIUM SALT
Common Name English
CHENODEOXYCHOLIC ACID SODIUM SALT
Common Name English
CHENODESOXYCHOLIC ACID SODIUM SALT
Common Name English
NSC-681066
Code English
SODIUM CHENODESOXYCHOLATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66913
Created by admin on Fri Dec 15 15:14:07 GMT 2023 , Edited by admin on Fri Dec 15 15:14:07 GMT 2023
Code System Code Type Description
FDA UNII
6V4571KSKE
Created by admin on Fri Dec 15 15:14:07 GMT 2023 , Edited by admin on Fri Dec 15 15:14:07 GMT 2023
PRIMARY
NCI_THESAURUS
C91034
Created by admin on Fri Dec 15 15:14:07 GMT 2023 , Edited by admin on Fri Dec 15 15:14:07 GMT 2023
PRIMARY
CAS
2646-38-0
Created by admin on Fri Dec 15 15:14:07 GMT 2023 , Edited by admin on Fri Dec 15 15:14:07 GMT 2023
PRIMARY
NSC
681066
Created by admin on Fri Dec 15 15:14:07 GMT 2023 , Edited by admin on Fri Dec 15 15:14:07 GMT 2023
PRIMARY
PUBCHEM
23696998
Created by admin on Fri Dec 15 15:14:07 GMT 2023 , Edited by admin on Fri Dec 15 15:14:07 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY